Stabilizing volatile liquid chemicals using co-crystallization

Aakeröy, Christer B.; Wijethunga, Tharanga K.; Benton, Joshua R.; Desper, John

doi:10.1039/c4cc09650a

Cited by 76 publications

(65 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is expected that all these findings can find an application in crystal engineering because they expand the arsenal of supramolecular organizations which may be useful for solvent storage 69 or separation 70 and also in physical chemistry as they contribute to the understanding of solvation with halomethanes. We hope that our results open up an avenue to the generation of other diiodomethane associates and studies in this direction are underway in our group.…”

Section: Discussionmentioning

confidence: 99%

Diiodomethane as a halogen bond donor toward metal-bound halides

et al. 2017

View full text Add to dashboard Cite

A 1, 3,5,7,3,6, chloride platinumĲII) complex (1) was obtained via the metal-mediated double coupling of 2,3-diphenylmaleimidine with both nitrile ligands in trans-Compound 1 was then co-crystallized with diiodomethane forming solvate 1·½CH 2 I 2 . The XRD experiment reveals that this solvate displays the halogen bonds H 2 C(I)-I⋯Cl-Pt and hydrogen bonds I 2 C(H)-H⋯Cl-Pt, which join two complex and one CH 2 I 2 molecules in a heterotrimeric supramolecular cluster. Inspection of the CCDC database reveals only one example of the halogen bond H 2 C(I)-I⋯I-Pt between the CH 2 I 2 molecule and metal-coordinated halide in the structure of VEMWOA. In VEMWOA, CH 2 I 2 serves solely as a halogen bond donor with no hydrogen bond contribution. Results of the Hirshfeld surface analysis and DFT calculations (M06/DZP-DKH level of theory) followed by topological analysis of the electron density distribution within the formalism of Bader's theory (QTAIM method) for both 1·½CH 2 I 2 and VEMWOA confirmed the formation of these weak interactions. The evaluated energies of halogen bonds involving CH 2 I 2 are in the 2.2-2.8 kcal mol −1 range.

show abstract

Section: Discussionmentioning

confidence: 99%

Diiodomethane as a halogen bond donor toward metal-bound halides

et al. 2017

View full text Add to dashboard Cite

show abstract

“…They improve the storage stability and dissolution of certain APIs. Some enable the preparation of solid formulations containing intrinsically liquid, semi-solid, 13) or volatile APIs 14) without handling difficulties. The association of some technically problematic APIs such as paracetamol with certain coformers (e.g., trimethylglycine) assists their appropriate tableting by enhancing compressibility.…”

Section: Pharmaceutical Applications Of Cocrystalsmentioning

confidence: 99%

Characterization and Quality Control of Pharmaceutical Cocrystals

Izutsu¹,

Koide²,

Takata

et al. 2016

Chem. Pharm. Bull.

View full text Add to dashboard Cite

Recent active research and new regulatory guidance on pharmaceutical cocrystals have increased the rate of their development as promising approaches to improve handling, storage stability, and bioavailability of poorly soluble active pharmaceutical ingredients (APIs). However, their complex structure and the limited amount of available information related to their performance may require development strategies that differ from those of single-component crystals to ensure their clinical safety and efficacy. This article highlights current methods of characterizing pharmaceutical cocrystals and approaches to controlling their quality. Different cocrystal regulatory approaches between regions are also discussed. The physical characterization of cocrystals should include elucidating the structure of their objective crystal form as well as their possible variations (e.g., polymorphs, hydrates). Some solids may also contain crystals of individual components. Multiple processes to prepare pharmaceutical cocrystals (e.g., crystallization from solutions, grinding) vary in their applicable ingredients, scalability, and characteristics of resulting solids. The choice of the manufacturing method affects the quality control of particular cocrystals and their formulations. In vitro evaluation of the properties that govern clinical performance is attracting increasing attention in the development of pharmaceutical cocrystals. Understanding and mitigating possible factors perturbing the dissolution and/ or dissolved states, including solution-mediated phase transformation (SMPT) and precipitation from supersaturated solutions, are important to ensure the bioavailability of orally administrated lower-solubility APIs. The effect of polymer excipients on the performance of APIs emphasizes the relevance of formulation design for appropriate use.

show abstract

“…1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 The preparation of multicomponent crystals, i.e., cocrystals, salts, solvates, and hydrates is a well-established technique for forming new phase(s) and altering the physicochemical properties of drug materials. [1][2][3][4][5][6][7][8][9] Interestingly, recent studies have investigated the potential of multicomponent crystals containing combinations of drugs. [10][11][12][13][14][15] This family of crystals, in addition to providing technological advantages, also offers improved pharmacological benefits and patient compliance.…”

mentioning

confidence: 99%

Drug–Drug Multicomponent Crystals as an Effective Technique to Overcome Weaknesses in Parent Drugs

Putra

Furuishi

Yonemochi

et al. 2016

Crystal Growth & Design

View full text Add to dashboard Cite

An interesting multicomponent crystal consisting of drug–drug combination was synthesized. The multidrug crystals consisted of antidiabetic drugs glicalzide and metformin. Single crystal X-ray structure analysis revealed that this multicomponent crystal is salt-type multicomponent crystal. The physicochemical properties of this crystal were significantly different from those of the parent drugs. The multicomponent crystal showed impressive solubility and dissolution rate compared to that of the raw material of gliclazide. Also, the hygroscopicity issue in metformin was tackled by the formation of multicomponent crystal. These physicochemical property alterations were associated with the existence of hydrophilic channel structure, which was confirmed by microscopic analysis. Therefore, the weaknesses of each component were mutually solved.

show abstract

Stabilizing volatile liquid chemicals using co-crystallization

Cited by 76 publications

References 49 publications

Diiodomethane as a halogen bond donor toward metal-bound halides

Diiodomethane as a halogen bond donor toward metal-bound halides

Characterization and Quality Control of Pharmaceutical Cocrystals

Drug–Drug Multicomponent Crystals as an Effective Technique to Overcome Weaknesses in Parent Drugs

Contact Info

Product

Resources

About